The approval was based on the results of the largest prospective, randomized and double-blind clinical trial ever conducted in diabetic patients with moderate to severe complicated foot infection. Foot infections commonly occur in patients with diabetes and are known to be difficult to treat.
“Currently there are limited data available for helping clinicians decide on the most appropriate treatment for foot infections in diabetic patients,” said Dr Murray Abramson, medical director, Clinical Development, Infectious Diseases and Oncology at Merck and Co. “The study supporting this new indication for Invanz provides physicians with another proven option in the treatment of diabetic foot infections.”